Annonaceous acetogenin mimic AA005 induces cancer cell death via apoptosis inducing factor through a caspase-3-independent mechanism by Bing Han et al.
Han et al. BMC Cancer  (2015) 15:139 
DOI 10.1186/s12885-015-1133-0RESEARCH ARTICLE Open AccessAnnonaceous acetogenin mimic AA005 induces
cancer cell death via apoptosis inducing factor
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Background: Annonaceous acetogenins are a family of natural products with antitumor activities. Annonaceous
acetogenin mimic AA005 reportedly inhibits mammalian mitochondrial NADH-ubiquinone reductase (Complex I)
and induces gastric cancer cell death. However, the mechanisms underlying its cell-death-inducing activity are
unclear.
Methods: We used SW620 colorectal adenocarcinoma cells to study AA005 cytotoxic activity. Cell deaths were
determined by Trypan blue assay and flow cytometry, and related proteins were characterized by western blot.
Immunofluorescence and subcellular fractionation were used to evaluate AIF nuclear translocation. Reactive oxygen
species were assessed by using redox-sensitive dye DCFDA.
Results: AA005 induces a unique type of cell death in colorectal adenocarcinoma cells, characterized by lack of
caspase-3 activation or apoptotic body formation, sensitivity to poly (ADP-ribose) polymerase inhibitor Olaparib
(AZD2281) but not pan-caspase inhibitor Z-VAD.fmk, and dependence on apoptosis-inducing factor (AIF). AA005
treatment also reduced expression of mitochondrial Complex I components, and leads to accumulation of intracellular
reactive oxygen species (ROS) at the early stage. Blocking ROS formation significantly suppresses AA005-induced cell
death in SW620 cells. Moreover, blocking activation of RIP-1 by necroptosis inhibitor necrotatin-1 inhibits AIF translocation
and partially suppresses AA005-induced cell death in SW620 cells demonstrating that RIP-1 protein may be essential for
cell death.
Conclusions: AA005 may trigger the cell death via mediated by AIF through caspase-3 independent pathway. Our work
provided new mechanisms for AA005-induced cancer cell death and novel clues for cancer treatment via AIF dependent
cell death.
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Biochemical qualities of the Annonaceae (custard-apple)
family are not completely known due to its large size
(130 genera and 2300 species) [1]. Many Annonaceae
species have been used in folk medicine and as insecti-
cides [2]. Products from the Annonaceae family, collect-
ively called annonaceous acetogenins (AAs), are very* Correspondence: jywangls@shsmu.edu.cn
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unless otherwise stated.potent inhibitors of mammalian mitochondria NADH-
ubiquinone reductase (Complex I) [3]. To date, over 400
members of this compound family have been found,
most of which have been proven to exhibit high cyto-
toxic and antitumor activities [1]. Over the past few
years, we have successfully developed a series of AA mi-
metics. More interestingly, we found that some of these
analogues have significant selectivity between human can-
cer cells and normal cells [4]. AA005 shows the best in-
hibitory effect against several human cancer cell lines [5],
although its exact mechanisms are largely unknown.
Mitochondria are the central relay station for apoptotic
signal transduction. In response to apoptotic stimulus,is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cytoplasm, where cytochrome c forms an apoptosome with
Apaf-1 and caspase-9 and triggers the caspase cascade.
The most important caspase in this cascade is caspase-3,
which is cleaved and activated to transduce the apoptotic
signal [6,7]. Mitochondria can also release apoptosis-
inducing factor (AIF) to initiate caspase-independent cell
death [8,9]. The mitochondrial flavoprotein AIF is a
caspase-independent cell-death-inducing factor [10]. Dur-
ing apoptotic signaling without caspase-3 activation, AIF is
released from the mitochondria when the mitochondrial
membrane is permeabilized, then translocates to the nu-
cleus where it induces cell death by triggering chromatin
condensation and large-scale DNA fragmentation into
~50-kilobase strands with the help of other proteins such
as Endo G (C. elegans), CypA (mice) or FEN-1 [10-17].
Here we report that AA005 may trigger caspase-3-
independent cell death, mediated by AIF. Our work may
provide novel therapeutic clues for treating cancers via a
non-canonical apoptotic pathway.
Methods
Cell culture and treatments
Human colorectal adenocarcinoma cell line SW620,
breast cancer cell line BT-549, and U937 acute myelo-
monocytic leukemic cell line came from the Cell Bank of
Shanghai Institutes for Biological Sciences (Shanghai,
China); acute promyelocytic leukemia (APL) cell line
NB4 were kindly provided by Dr. M. Lanotte in France
[18]. These cells were cultured in RPMI-1640 medium
(Sigma-Aldrich, St Louis, MO) supplemented with 10%
heat-inactivated fetal calf serum (FCS; HyClone, Logan,
UT) in a 5% CO2 humidified atmosphere at 37°C. For
experiments, cells were seeded at 2–5 × 105 cells/ml and
incubated with the indicated concentrations of AA
mimic AA005 (kindly provided by Institute of Chemical
Biology and Drug Innovation, School of Chemistry and
Chemical Engineering, Nanjing University, Nanjing,
China), MNNG (Sigma-Aldrich), and camptothecin
(kindly provided by National Cancer Institute Anticancer
Drug Screen standard agent database, Bethesda, MD) with
or without caspase inhibitor Z-VAD.fmk (Sigma-Aldrich).
AA mimic AA005 were dissolved in 75% ethanol as a
1 mM stock solution and was kept at −80°C. MNNG
(100 mM) was freshly prepared in dimethylsulfoxide
(DMSO) and diluted in culture media to 0.5 mM. After
treatment for 15 min, cells were washed and returned to
the normal growth medium. camptothecin was dissolved
in double-distilled water as a 1 mM stock solution. Z-
VAD.fmk was dissolved in DMSO before use.
Trypan blue assay
After treatments cells were harvested, resuspended in
cell growth medium, and diluted 1:1 with 0.4% trypanblue stain (Sigma-Aldrich). Stained and unstained cells
were counted using a hemocytometer.
TUNEL assay
Cells were seeded in 6-well plates 1 day prior to treat-
ments. Fragmented DNA was assessed using terminal
deoxynucleotidyl transferase (TdT)-dUTP nick end-
labeling (TUNEL) kit (Roche) according to the manufac-
turer’s protocol.
DNA gel electrophoresis
Appropriate 106 cells were harvested, and pellets were sus-
pended in lysis buffer (0.1 M NaCl, 50 mM Tris–HCl,
pH 7.5, 10 mM EDTA (ethylenedia-minetetraacetic acid),
0.5% sodium dodecyl sulfate [SDS], 500 μg/ml protease
K). After a 30 minutes, incubation on ice, samples were
centrifuged at 14,000 g for 30 minutes, and cellular DNA
was extracted. The samples were electrophoresed in 2%
agarose gel at 100 V in 40 mM Tris-acetate buffer
(pH 7.4) and visualized by ethidium bromide staining.
Flow cytometric assays for Annexin-V
Briefly, about 106 cells were rinsed with phosphate-
buffered saline (PBS), and Annexin-V assay was per-
formed on a flow cytometry (Beckman Coulter) accord-
ing to instructions provided by the ApoAlertAnnexin-V
kit (Clontech, PaloAlto, CA) as well as stained with
50 μg/ml propidium iodide (PI; Sigma).
RNA interference and transfection
For siRNA in SW620 cells, the following oligonucleotides
were inserted into RNAi-Ready pSIREN-RetroQ vector
(Clontech, Palo Alto, CA): 5′-TAGCGGTCGCCGAA
ATGTT-3′ (A3) and 5′-CTGGTATCCGATCAGAGAG-3′
(A5) for AIF, and 5′-ACTACCGTTGTTATAGGTG-3′ for
scrambled negative control. Retrovirus with these shRNA
produced in 293 T cells were used to infect SW620 cells.
Stable retroviral transduction was achieved by infection
for 48 h, after which selection with puromycin was initi-
ated. Selection was stopped as soon as the non-infected
control cell died off. Media were then replaced with nor-
mal growing medium.
Western blots
The protein lysates were mixed with equal volume of
Laemmli buffer (62.5 mM Tris–HCl, pH 6.8, 2% sodium
dodecyl sulfate, 50 mM Dithiothreitol, 10% glycerol,
0.01% bromophenol blue), boiled for 3 min at 100°C and
then resolved by sodium dodecyl sulfate–polyacrylamide
gel electrophoresis on a 10%–12% gel using a mini gel
apparatus (Bio-Rad, Hercules, CA). Subsequently, the
proteins were electrophoretically transferred to a nitro-
cellulose membrane (Bio-Rad). The membranes were
blocked with 5% nonfat dry milk solution in Tris-
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temperature and then incubated in primary antibody dis-
solved in block solution at 4°C overnight. The proteins
were probed by antibodies against AIF (Cell Signaling,
Beverly, MA), with mouse anti-β-actin mAb (Merck,
Darmstadt, Germany) to confirm equal loading. After
washing, the blots were incubated with horseradish
peroxidase-conjugated secondary antibody (Dako Cytoma-
tion, Glostrup, Denmark) corresponding to the primary
antibody in blocking buffer for 1 h at room temperature,
and detections were performed by Super Signal West Pico
Chemiluminescent Substrate kit (Pierce, Rockford, IL) ac-
cording to the manufacture’s instructions.
Immunofluorescence
Colorectal adenocarcinoma cells were crawled onto
cover slides, fixed with 4% paraformaldehyde and
permeabilized with 0.3% Triton X-100 for 10 min. SlidesFigure 1 AA005 induces cell death in various cancer cell lines. (A) Chem
cells of SW620 (B) and BT549 (C), leukemic cells of U937 (D) and NB4
Cell death was measured by trypan-blue exclusion assay; each column
experiment. *P < 0.05, **P < 0.01, compared with the vehicle-only controwere blocked with 1% bovine serum albumin and incu-
bated with rabbit anti-AIF monoclonal antibody (1:100)
overnight at 4°C. After washing in PBS, the cells were
stained with secondary antibodies (FITC-conjugated bo-
vine antirabbit; 1:200; Santa Cruz Biotech) and incubated
for 1 h in room temperature, followed by nuclear coun-
terstaining with DAPI. Fluorescence signals were de-
tected on a Olympus BX-51 fluorescence microscope
(Tokyo, Japan).
Detection of ROS by flow cytometry
Cells were washed with phosphate-buffered saline (PBS),
re-suspended in pre-warmed PBS (37°C), and incubated
with 10 mM 5-(and 6)-chloromethyl-2′,7′-dichlorodihy-
drofluorescein diacetate, acetyl ester (C-6827, CM-H2-
DCFDA, Invitrogen, Carlsbad, CA, USA) for 30 min at 37°C.
Cells were then washed with PBS twice and scraped into
0.3 ml of ice-cold PBS. CM-H2-DCFDA fluorescenceical structures of annonaceous acetogenin mimic AA005. (B–E) Adherent
(E), were treated with AA005 at indicated concentrations for 48 h.






Figure 2 AA005 induces non-canonical apoptotic cell death. (A) SW620 cells were treated with or without 20 μM camptothecin, 1 μM
AA005, or 500 μM MNNG, for 36 h, 48 h or 8 h. Images were viewed using an Olympus BX-51 fluorescence microscope. Treatment with MNNG
and camptothecin were used as controls. Scale bars: 100 μm. (B) SW620 cells were treated with 1 μM AA005 for 24 h or 48 h. Annexin-V/PI
double-stained cells were measured by flow cytometry. Panels show percentages of Annexin-V+ or PI+ cells. Right: dead cells. Each column
represents mean ± S.D. from an independent experiment performed in triplicate. **P < 0.01, compared with vehicle-only control. (C) TUNEL
analysis of SW620 cells treated with 20 μM camptothecin, 1 μM AA005 and 500 μM MNNG. Images were viewed using an Olympus BX-51 fluorescence
microscope. Scale bars: 20 μm. (D) Percentages of TUNEL+ cells were determined in 200 cells per sample and assessed in 3 independent experiments.
Results show mean ± S.D. *P < 0.05, **P < 0.01, compared with vehicle-only control. (E) SW620 cells were incubated with 20 μM camptothecin, 1 μM
AA005 or 500 μM MNNG for 36 h, 48 h or 8 h. DNA samples from these treated cells were electrophoresed in a 2% agarose gel.
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ple following excitation with a 488-nm wavelength
laser and reading through a 530/30 filter (FACSCalibur,
BD Bioscience, San Jose, CA, USA).
Statistical analysis
Each experiment was done independently at least 3 times
with similar results. Results are expressed as mean ± S.D.
Significant differences were assessed with the Student’s t
test (2-tailed). P < 0.05 was considered to be significant.
Results
AA005 induces cell death in various cancer cell lines
To evaluate the potential cytotoxicity of AA mimic AA005
(Figure 1A) [19], we administered AA005 to colorectal
adenocarcinoma cell line SW620, breast cancer cell line
BT-549, acute promyelocytic leukemia cell line NB4, and
acute myelomonocytic leukemic cell line U937, followed by
cell viability analysis with trypan-blue exclusion assays.Figure 3 AA005 induces cell death through caspase-3-independent m
AA005 for the indicated times. Treatment with 20 μM camptothecin for 36
detected by western blot, standardized to actin. ΔPARP-1, and ΔCaspase-3
fragment proteins, respectively. (B) SW620 cells were preincubated with 10
for 48 h, and with 20 μM camptothecin for 36 h. Annexin-V/PI double-stain
show mean ± S.D. *P < 0.05, versus camptothecin-treated group. (C, D) NB
treated with or without 1 μM camptothecin (C), or 1 μM AA005 (D), for ind
measured on flow cytometry. Values show mean ± S.D. of triplicates in anPercentages of dead cells were 19.01 ± 2.10%, 50.79 ± 1.81%,
66.20 ± 0.80% and 69.55 ± 3.68% respectively, when SW620
cells were treated with 0.2 μM, 1 μM, 5 μM and 25 μM
AA005 for 48 h (Figure 1B). Similar results were obtained
in other cell lines (Figure 1C, D, E). These results showed
that the cell-death inducing activity of AA005 was general
and dose-dependent.
AA005 induces non-canonical apoptosis
To investigate the biochemical and morphological changes
during the process of AA005-induced cell death, SW620
cells were treated with AA005, N-methyl-N’-nitro-N-nitro-
soguanidine (MNNG) [20], and camptothecin [21]. MNNG
and camptothecin were used as controls for caspase-
independent and caspase-dependent cell death, respect-
ively. AA005-induced cell death was clearly different
from camptothecin-induced cell death, which was charac-
terized by membrane shrinking, nuclear condensation,
and disintegration of the dying cell into apoptotic bodies.echanisms. (A) SW620 cells were treated with or without 1 μM
h was used as positive control. Proteins PARP-1, and caspase-3 were
indicate cleaved 85-kDa fragment of PARP-1 and active Caspase-3
0 μM Z-VAD.fmk for 1 h and then treated with or without 1 μM AA005
ed cells and cell death were measured by flow cytometry. Results
4 cells were preincubated with 40 μM Z-VAD.fmk for 1 h and then
icated times. Annexin-V/PI double-stained cells and dead cells were
independent experiment.
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induced cell death during which massive cell death was
triggered instantly at a certain time point, followed by the
formation of cell membranes rupture, dissolution of orga-
nized structures and semi-circular shadows emerged
around the dying cells (Figure 2A). Annexin-V/PI double
stain-based flow cytometry analysis is the most sensitive
and specific test for determining apoptotic cells, which are
classified as Annexin-V+/PI−cells [22]. Although nearly 50%
of cells died at 48 h of AA005 treatment, no obvious
Annexin-V+/PI−cells were detected throughout this processFigure 4 AA005 promotes translocation of AIF to cell nuclei. (A) Flow
presence of PARP inhibitor Olaparib (AZD2281; 50 μM). Panel numbers sho
column shows mean ± S.D. of triplicates in an independent experiment. **
translocation by subcellular fractionation. SW620 cells 48 hours after AA005
subjected to subcellular fractionation; immunoblotting was performed with
as nuclear and mitochondrial marker proteins, respectively. (C) NB4 cells w
subjected to subcellular fractionation; immunoblotting was performed with n
nuclear and mitochondrial marker proteins. (D) SW620 cells grown on chamb
Subcellular localization of AIF protein was examined by Olympus BX-51 fluore
cells were inspected per experimen; cells with typical morphology are shown
times with similar results.(Figure 2B), indicating that AA005-induced cell death is
not classical apoptosis. Furthermore, TUNEL analysis [23]
of AA005-, camptothecin- and MNNG-treated SW620
cells are shown in Figure 2C. Although all three agents in-
duced TUNEL+ cells, AA005 and MNNG showed stron-
ger effects than camptothecin (Figure 2C, D). However,
DNA fragmentation analysis indicated that camptothe-
cin but not AA005 or MNNG induced apoptosis-
specific DNA-ladders (Figure 2E). These results indicate
that AA005 induced non-canonical apoptotic cell death
in SW620 cells.cytometry analysis of AA005- or MNNG-induced cell death in the
w percentages of Annexin-V+ or PI+ cells. Lower: dead cells. Each
P < 0.01, versus AA005- or MNNG-treated group. (B) Analysis of AIF
treatment, 8 hours after MNNG treatment or control cells were
nuclear and mitochondrial fractions. Lamin B and COX IV were used
ere treated with or without 1 μM AA005 for indicated times and
uclear and mitochondrial fractions. Lamin B and COX IV were used as
er slides were treated with or without 1 μM AA005 or 500 μM MNNG.
scence microscope analysis. DAPI: DAPI nuclear counterstaining. > 100
. Scale bars, 20 μm. The experiments in B–D were repeated at least three
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pathway
To elucidate the mechanisms of AA005-induced cell
death, we analyzed the involvement of caspase-3, an
important executing caspase of apoptosis. Camptothe-
cin treatment was used as a positive control. AA005
treatment failed to trigger cleavage of caspase-3 and its
substrate PARP-1, even when cell death was as high as
55% (Figure 3A). Additionally, Z-VAD.fmk, a broad-
spectrum caspase inhibitor, greatly blocked camptothecin-
induced cell death, but showed no effect on AA005-
induced cell death (Figure 3B). To further investigate
whether caspase-3 played a role in AA005-induced cell
death, we also tested caspase-3 activation in NB4 cells.
Similarly, Z-VAD.fmk blocked most cell death trig-
gered by camptothecin (Figure 3C), but had no effect
on the cell death induced by AA005 in NB4 cells
(Figure 3D). Taken together, these results suggested
that AA005 induced cell death through caspase-3 inde-
pendent mechanisms.Figure 5 AA005-induced cell death significantly decreases in AIF knoc
negative control (NC) or siRNAs against AIF (A3 or A5); absence of AIF expr
(B–D) AIF knockdown SW620 cells and controls were treated with or witho
camptothecin for 36 h (D). Annexin-V/PI double stained cells and cell deat
times with the same results. Results show mean ± S.D. **P < 0.01, versus AAAIF potentially contributes to AA005-induced cell death
Our data showed that AA005-induced cancer cell death
left morphology similar to that of MNNG-treated cells. Re-
portedly, MNNG-mediated cell death was AIF-mediated
and PARP-1 dependent, resulting in a caspase-independent
type of apoptosis, called parthanatos [20,24,25]. Interest-
ingly, the mitochondrial flavoprotein AIF is well known as
a caspase-independent apoptosis inducer [10]. For this rea-
son, we speculated whether AIF played a role in
AA005-induced cell death. We found that inhibition of
PARP by Olaparib (AZD2281) [26] in SW620 cells
completely blocked AA005 or MNNG-induced toxicity
(Figure 4A). Under physiological conditions, AIF re-
sides in the inter-membrane space of mitochondria
and plays an essential role in maintaining mitochon-
drial function [27,28]. When it is released from mito-
chondria and translocates to the nucleus, it induces
chromatin condensation and large-scale DNA cleavage in
response to death stimuli [29]. We used immunofluores-
cence assay and subcellular fractionation to evaluate AIFkdown cells. (A) SW620 cells were transfected with scrambled
ession was confirmed by western blot analysis, standardized to actin.
ut 1 μM AA005 for 48 h (B), 500 μM MNNG for 8 h (C), and 20 μM
h were measured on flow cytometry. All experiments were repeated 3
005- or MNNG-treated NC group.
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readily observed by treatment with AA005 or the positive
control MNNG in SW620 cells (Figure 4B), and similar
findings in NB4 cells (Figure 4C). Immunofluorescence as-
says also showed AIF translocation into the nucleus after
treatment with AA005 or MNNG (Figure 4D). Together,
these results indicated that AA005 promotes AIF nuclear
translocation.
To assess involvement of AIF, SW620 cells were trans-
fected with retrovirus harboring NC or siRNAs against
AIF (designated as A3 and A5; Figure 5A). Absence of
AIF expression was confirmed by western blot analysis
(Figure 5A). Furthermore, AIF knockdown almost
completely blocked the cell death induced by AA005
(Figure 5B). We also confirmed that AIF knockdown
inhibited the cell death induced by MNNG, the action of
which is reportedly mediated by AIF (Figure 5C) [20], but
had no effect on camptothecin-induced cell death, which
is caspase-dependent (Figure 5D). Together, these results
indicate that AA005 promote AIF nuclear translocation
and trigger AIF-dependent cell death.
ROS mediates AA005-induced cell death of SW620 cells
Because release of AIF from the mitochondria and trans-
location to the nucleus occurred too late during AA005-Figure 6 ROS mediates AA005-induced cell death of SW620 cells. (A)
times. Complex I subunits NDUFS1 and NDUFA10 were detected by weste
without AA005 at 1 μM for 1 h, 4 h or 12 h. DCFDA staining was then analyze
3 times with the same results. Results show mean ± S.D. *P < 0.05, **P < 0.01, c
without 1 mM NAC for 2 h, cells were treated with or without AA005 at 1 μM
cytometry. Panels show percentages of Annexin-V+ or PI+ cells (D). Dead cells
experiment. **P < 0.01, vs AA005-treated group.induced cell death, the intrinsic cell death signaling at
the early stage initiated by AA005 should be further in-
vestigated. Evidence from other studies suggests that
AAs are potent inhibitors of mitochondrial NADH-
ubiquinone reductase (Complex I) [3]. Based on this
clue, we tested protein levels of Complex I subunits dur-
ing AA005-induced cell death. Protein levels of Complex
I subunits NDUFS1 and NDUFA10 decreased signifi-
cantly after AA005 treatment (Figure 6A). Increased
ROS concentrations caused by depletion of mitochon-
drial proteins led to activation of cell death signaling
[30]. As we had shown AA005 treatment to decrease
mitochondrial Complex I subunits, we next investigated
ROS production during AA005-induced cell death. To
address whether oxidative stress contributes to re-
sponses to AA005, SW620 cells were treated with
AA005 at 1 μM for 1 h, 4 h or 12 h, followed by incuba-
tion with fluorophore dichlorodihydrofluorescein diace-
tate (DCFDA), a dye to monitor intracellular ROS, for
30 min. As expected, intracellular concentrations of
ROS were significantly increased immediately after
AA005 treatment and ROS levels maintained high from
1 h to 12 h (Figure 6B, C). Importantly, elevated ROS
levels were necessary to mediate AA005-induced cell
death, in that N-acetyl-L-cysteine (NAC), an efficientSW620 cells were treated with or without 1 μM AA005 for indicated
rn blot, standardized to actin. (B−C) SW620 cells were treated with or
d on flow cytometry (B); quantified data: (C). Experiments were repeated
ompared with vehicle-only control. (D, E) After pretreatment with or
for 60 h. Annexin-V/PI double-stained cells were measured on flow
(E). Each column shows mean ± S.D. of triplicates in an independent
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(Figure 6D, E).
RIP1 is required for AA005-induced cell death
In our study, we showed that a previously unknown
caspase-independent–AIF-dependent cell death was in-
duced by AA005, and mediated through ROS. However,
the underlying mechanisms remain unclear. The present
study reported that the receptor interacting proteinFigure 7 RIP1 is required for AA005-induced cell death. (A) Immunobl
treatment or 8 h MNNG treatment for the indicated times, standardized to
death in the presence of RIP-1 inhibitor Necrostatin-1 (Nec-1; 100 μM).
*P < 0.05 versus AA005- or MNNG-treated group). (C) Immunoblotting analy
either RIP-1 inhibitor Necrostatin-1 (Nec-1; 100 μM) or PARP inhibitor Olapar
mitochondrial marker proteins, respectively. (D) SW620 cells were transfecte
siRNAs against AIF (designated as A3 and A5). AIF and RIP-1 were examined
were repeated at least three times with similar results.(RIP)-1, a critical mediator of necroptosis, could modu-
late oxidative stress in AIF-dependent cell death [31,32].
To better understand the mechanisms, we examined the
expressional level of RIP-1, and found it was up-
regulated significantly in SW620 cells at 24 h with
AA005 treatment (Figure 7A). We speculated that RIP-1
might participate in AA005-induced cell death. Inhib-
ition of RIP-1 by Necrostatin-1 (Nec-1) in SW620 cells
ameliorated cell death and AIF translocation afterotting analysis of the expressional level of RIP-1 after 1 μM AA005
actin. (B) Flow cytometry analysis of AA005 or MNNG induced cell
Numbers are mean values of three independent experiments ± S.D.
sis of AIF translocation by subcellular fractionation in the presence of
ib (AZD2281; 50 μM). Lamin B and COX IV were used as nuclear and
d with retrovirus harboring either scrambled negative control (NC) or
by western blots, standardized to actin. Experiments in (A), (C) and (D)
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down failed to affect the increase in RIP-1 evoked by
AA005 (Figure 7D). These observations imply that RIP-
1 activation is required for AIF translocation from the
mitochondria to the nucleus and that RIP-1 is necessary
for AIF-dependent cell death induced by AA005.
Discussion
Directed induction of cell death could provide therapeutic
benefits for cancer treatment. Such treatments mainly tar-
get caspase pathways to induce apoptosis. However, cas-
pase activation may be dispensable for some kinds of
apoptosis, and increasing attention has been drawn to key
molecules involved in non-apoptotic cell death or caspase-
independent apoptosis [10,33]. The mitochondrial protein
AIF is a new therapeutic target involved in most of the
caspase-independent apoptosis systems, including pro-
grammed necrosis [34].
In this work, we found that AA005 could induce cell
death of SW620 cells and NB4 cells with evidence that
implies a caspase-independent mechanism; we also
found that AIF might be involved in this process. We
also found that AA005-induced death of cancer cells pro-
vides a morphology similar to that of MNNG treated cells.
Previous studies indicated that MNNG-mediated cell
death was AIF-mediated and PARP-1-dependent, resulting
in a caspase-independent type of apoptosis, called partha-
natos [20,25]. Our findings indicate that AA005 targets
AIF signaling by promoting its nuclear translocation. The
fact that AA005-induced cell death is mostly blocked by
AIF knockdown suggests that AIF is crucial to AA005-
induced cell death.
It has previously been reported that AAs were very po-
tent inhibitors of the mitochondrial NADH-ubiquinone re-
ductase (Complex I) and induced apoptosis by reducing
intracellular cAMP and cGMP levels in human cancer
[3,35]. Recently, Liu et al. revealed that AA005 co-localized
with mitochondria in colon cancer cells. In their view,
AA005 could activate AMP-activated protein kinase
(AMPK) and inhibit the mTOR complex 1 (mTORC1) sig-
nal pathway, leading to growth inhibition and autophagy of
colon cancer cells. However, AMPK inhibitors compound
C and inosine can only partially attenuate AA005-caused
proliferation suppression of colon cancer cells [36], indicat-
ing that other mechanisms affect the cancer suppression
activity of AA005. In addition, the mechanism of Complex
I inhibition by AA005 is unclear, although AIF is known to
affect Complex I activity [24]. In fact, here we find that
AA005 treatment decreased mitochondrial Complex I sub-
units, and significantly increased intracellular concentra-
tions of ROS. AA005, as a novel ROS-inducing agent, may
be an effective chemical probe to examine the mechanisms
of tumor cells that are more sensitive and vulnerable to
toxic oxidative stress [37]. Our research here shows RIP-1activation is required for translocation of AIF from the
mitochondria to the nucleus; and AIF is necessary for
AA005-induced cell death, which is prevented by PARP in-
hibitors, RIP-1 inhibitors or knockdown of AIF, but is cas-
pase independent. We speculate that AA005 may disrupt
mitochondrial function by reducing mitochondrial Com-
plex I expression, thus triggering ROS, RIP and AIF-
dependent pathway. Thus provides a new clue to the action
of AA005.
As a core executor in caspase-independent cell death,
AIF is intensively studied [11]. However, many studies’
results are highly controversial. We suggest that AA005
is an effective chemical probe to examine the role of
AIF. Furthermore, AA005 may be the basis of a novel
treatment for cancers that are resistant to classical apop-
totic reagents.
Conclusions
AA005 can induce an AIF-dependent but caspase-
independent cell death, which is mediated through ROS
and RIP1. Our work shows new mechanisms for AA005-
induced cancer cell death and implies a novel cancer treat-
ment via AIF dependent cell death.
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